UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

Mark One

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                            to                          

 

Commission File No. 333-234487

 

NOWTRANSIT INC.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or Other Jurisdiction of

Incorporation or Organization)

7374

(Primary Standard Industrial

Classification Number)

98-1498782

(IRS Employer

Identification Number)

 

2722 South West Temple

Salt Lake City, UT 84115

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (801) 949-0791

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

None

None

 

Securities registered pursuant to Section 12(g) of the Act: Common stock, par value $0.0001

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated Filer ☐

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the practicable date:

 

Class

Outstanding as of August 8, 2023

Common Stock: $0.0001 par value

40,392,600
 

 

 

TABLE OF CONTENTS

 

PART 1

FINANCIAL INFORMATION

 

Item 1.

Financial Statements

3

 

Balance Sheets (unaudited)

3

 

Statements of Operations (unaudited)

4

 

Statement of Changes in Stockholders’ Equity (Deficit) (unaudited)

5

 

Statements of Cash Flows (unaudited)

6

 

Notes to Financial Statements (unaudited)

7

Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations

11

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

14

Item 4.

Controls and Procedures

14

 

 

 

PART II

OTHER INFORMATION

15

Item 1.

Legal Proceedings

15

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

15

Item 3.

Defaults Upon Senior Securities

15

Item 4.

Mine Safety Disclosures

15

Item 5.

Other Information

15

Item 6.

Exhibits

16

 

Signatures

17

 

 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company's December 31, 2022 audited financial statements and notes thereto. Operating results for the six months ended June 30, 2023 are not necessarily indicative of the results that can be expected for the year ending December 31, 2023.

 

NOWTRANSIT INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 
                 
   

June 30,

   

December 31,

 
   

2023

   

2022

 
   

(Unaudited)

         

ASSETS

               

Current Assets

               

Cash and cash equivalents

  $ 30,317     $ 11,569  

Accounts receivable, net

    15,820       7,761  

Inventory

    15,830       12,278  

Prepaid Expenses

    1,000       -  

Total current assets

    62,967       31,608  
                 

Total Assets

  $ 62,967     $ 31,608  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

               

Current Liabilities

               

Accounts payable

  $ 901     $ 3,435  

Due to related parties

    116,318       45,356  

Total current liabilities

    117,219       48,791  
                 

STOCKHOLDERS' EQUITY (DEFICIT)

               

Preferred stock: $0.0001 par value, 5,000,000 shares authorized;

1,000,000 designated Series A Convertible

    -       -  

Preferred stock: $0.0001 par value, 140,000 shares

authorized; 140,000 shares issued and outstanding at

June 30, 2023 and December 31, 2022

    14       14  

Common stock: $0.0001 par value, 75,000,000 shares authorized;

40,312,600 and 5,461,500 shares issued and outstanding at

June 30, 2023 and December 31, 2022, respectively

    4,031       546  

Additional paid-in capital

    274,264       158,840  

Accumulated deficit

    (332,561 )     (176,583 )

Total stockholders' equity (deficit)

    (54,252 )     (17,183 )

Total Liabilities and Stockholders' Equity (Deficit)

  $ 62,967     $ 31,608  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

NOWTRANSIT INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Unaudited)

 
                                 
   

For the Three

Months Ended

   

For the Six

Months Ended

 
   

June 30,

   

June 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Revenues

  $ 69,465     $ 8,049     $ 101,802     $ 8,328  

Cost of goods sold

    (9,499 )     (982 )     (14,245 )     (1,047 )

Gross profit

    59,966       7,067       87,557       7,281  
                                 

Operating Expenses:

                               

General and administrative expenses

    138,728       8,445       231,035       8,595  

Consulting fees

    6,500       500       12,500       4,775  

Total Operating Expenses

    145,228       8,945       243,535       13,370  
                                 

Loss from Operations

    (85,262 )     (1,878 )     (155,978 )     (6,089 )
                                 

Net loss

  $ (85,262 )   $ (1,878 )   $ (155,978 )   $ (6,089 )
                                 

Net loss per common share - basic and diluted

  $ (0.01 )   $ (0.00 )   $ (0.01 )   $ (0.00 )

 

                               

Weighted average common shares outstanding - basic and diluted

    39,841,872       9,400,000       26,775,330       7,274,309  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

NOWTRANSIT INC

 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

 

FOR THE SIX MONTHS ENDED

 

JUNE 30, 2023 & 2022

 

(Unaudited)

 
                                   

Additional

                 
   

Common Stock

   

Preferred Stock

   

Paid-in

   

Accumulated

         
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Deficit

   

Total

 
                                                         

Balance at December 31, 2021

    2,890,951     $ 289       -     $ -     $ 4,836     $ (6,133 )   $ (1,008 )

Common shares issued for services

    2,284,556       228       -       -       3,822       -       4,050  

Common shares issued to related

parties for services

    126,920       13       -       -       212       -       225  

Net loss

    -       -       -       -       -       (4,211 )     (4,211 )

Balance at March 31, 2022

    5,302,427       530       -       -       8,870       (10,344 )     (944 )

Net Loss

    -       -       -       -       -       (1,878 )     (1,878 )

Balance as June 30, 2022

    5,302,427     $ 530       -     $ -     $ 8,870     $ (12,222 )   $ (2,822 )
                                                         

Balance at December 31, 2022

    5,461,500     $ 546       140,000     $ 14     $ 158,840     $ (176,583 )   $ (17,183 )
                                                         

Recapitalization March 10, 2023

    34,371,100       3,437       -       -       (4,528 )     -       (1,091 )

Net loss

    -       -       -       -       -       (70,716 )     (70,716 )

Balance at March 31, 2023

    39,832,600       3,983       140,000       14       154,312       (247,299 )     (88,990 )

Common shares issued for cash

    480,000       48       -       -       119,952       -       120,000  

Net Loss

    -       -       -       -       -       (85,262 )     (85,262 )

Balance as June 30, 2023

    40,312,600     $ 4,031       140,000     $ 14     $ 274,264     $ (332,561 )   $ (54,252 )

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

NOWTRANSIT INC. AND SUBSIDIARY

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited)

 
                 
   

For the Six Months Ended

 
   

June 30,

 
   

2023

   

2022

 
                 

Cash Flows From Operating Activities

               

Net loss

  $ (155,978 )   $ (6,089 )

Adjustments to reconcile net loss to net cash used in

operating activities:

               

Stock issued to related parties for services

    -       225  

Stock issued for services

    -       4,050  

Changes in operating activities:

               

Accounts receivable

    (8,059 )     (772 )

Inventory

    (3,552 )     (9,828 )

Prepaid expenses

    (1,000 )        

Accounts payable

    (12,418 )     1,252  

Net Cash Used in Operating Activities

    (181,007 )     (11,162 )
                 

Cash Flows From Investing Activities

    -       -  
                 

Cash Flows From Financing Activities

               

Advances from related parties

    180,574       38,292  

Repayment to related parties

    (109,612 )     (19,002 )

Cash acquired in recapitalization

    8,793       -  

Stock issued for cash

    120,000       -  

Net Cash Provided by Financing Activities

    199,755       19,290  

Net Increase in Cash

    18,748       8,128  

Cash at Beginning of Period

    11,569       100  

Cash at End of Period

  $ 30,317     $ 8,228  
                 

Supplemental Cash Flow Information:

               

Cash paid for interest

  $ -     $ -  

Cash paid for income taxes

  $ -     $ -  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

 

NOWTRANSIT INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

(Unaudited)

 

Note 1 - Nature of Organization

 

Nowtransit Inc. (the “Company,” “us,” “we,” “Nowtransit”) was incorporated in the State of Nevada on July 8, 2019. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. (“Best”), a Nevada corporation, wherein we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company (see Note 2).

 

Best was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels. Presently, the Company is selling Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, Be On-Guard Brain Fog Support, ADHD 365 maximum brain support, and EZ Safer Surface Cleaner.

 

Note 2 - Reorganization & Recapitalization

 

On February 13, 2023, Nowtransit entered into a Share Exchange Agreement with Best and the shareholders of Best who collectively owned 9,588,000 shares of Best common stock, or 100% of the outstanding shares of Best common stock. The transaction consummated on March 10, 2023 (the “Closing”).

 

Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock (see Note 6), representing approximately 85.39% of the shares of the Company’s common stock to be outstanding, in exchange for all of the shares of Best common stock held by Best shareholders. The transaction was accounted for as a reserve merger by Nowtransit and resulted in a recapitalization with Best being the accounting acquirer and Nowtransit being the accounting acquiree. As such, the consolidated financial statements presented are the historical financial statements of Best with retroactive adjustments to reflect the equity of Nowtransit, and the operations of Nowtransit from March 10, 2023, the effective date of the merger. Since Nowtransit was the legal acquirer, the resulting financial statements are in the name of Nowtransit. All share and per share information in the accompanying condensed consolidated financial statements and footnotes have been retroactively restated to reflect the recapitalization.

 

The following table summarizes the assets acquired and the liabilities assumed at the acquisition date of March 10, 2023:

 

Cash

  $ 8,793  

Accounts Payable

    (8,870

)

Credit Card Liability

    (1,014

)

Net Assets (Liabilities) Assumed

  $ (1,091

)

 

During the three months ended March 31, 2023 the Company reported $0 in revenue and $5,295 in expenses for the accounting acquiree (Nowtransit) since the acquisition date (March 10, 2023). Had Nowtransit and Best been combined since January 1, 2023 they would have reported revenues of $32,337, gross profit of $27,591, total operating expenses of $117,417, and a net loss of $89,826.

 

Note 3 - Going Concern

 

The condensed consolidated financial statements have been prepared on a going concern basis which assumes the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

 

As reflected in the condensed consolidated financial statements, the Company had minimal revenues and a net loss during the six months ended June 30, 2023 and is showing total liabilities in excess of total assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company is attempting to commence full-scale operations and generate sufficient revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations long-term. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.

 

 

Note 4 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and19 Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars and the Company has adopted a December 31 year end.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of June 30, 2023 and December 31, 2022, the Company had no cash equivalents.

 

The Company maintains one account at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of June 30, 2023 and December 31, 2022, the allowance for doubtful accounts was $0.

 

Inventory

 

The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of June 30, 2023 and December 31, 2022 the Company had $15,830 and $12,278 of finished goods on hand, respectively.

 

Income Taxes

 

The provision for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.

 

 

Revenue Recognition

 

The Company’s revenue is recognized in accordance with Accounting Standards Codification 606. The Company, through its online websites, operates in the Immune health supplement market. In addition to the website the Company has a Seller Central listing with Amazon and sells three products through the Amazon online platform. The Company offers products – Be-OnGuard Nasal Spray used against nasal bacteria, viruses and allergens; Be-OnGuard Mouth Spray used against oral bacteria, viruses and allergens; and Be-OnGuard EZ Safer Air used against airborne bacteria, viruses and allergens; Be On-Guard Brain Fog Support; and ADHD 365 maximum strength brain support. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers will remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. As of June 30, 2023 and December 31, 2022 deferred revenue was $0. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue.

 

Advertising Costs

 

Advertising costs are expensed as incurred. During the six months ended June 30, 2023 and 2022, the Company incurred advertising costs of $ 47,675 and $0, respectively.

 

Leases

 

The Company follows the provisions of ASC 842, and records right-of-use ("ROU") assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments.  The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.

 

The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

 

As of June 30, 2023, the Company had a month-to-month rental agreement for their office and inventory space and paid rent expense of $3,584 for the six months ended June 30, 2023.

 

Net Income (Loss) per Common Share

 

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. There were no potentially dilutive common shares outstanding as of June 30, 2023 or 2022.

 

Recent Accounting Pronouncements

 

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements.

 

Note 5 - Related Party Transactions

 

In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. Amounts represent advances or amounts paid in satisfaction of liabilities.

 

During the six months ended June 30, 2023 the Company purchased $19,950 worth of inventory from Ageless Holdings, LLC (“Ageless”), an entity owned and controlled by the Company’s members of management and board of directors, $12,857 was owing as of June 30, 2023. Additionally, the Company received $180,574 worth of advances from Ageless to pay for operating expenses and the Company paid back $109,612 of the advances.

 

 

As of June 30, 2023 and December 31, 2022, the Company owed related parties a total of $116,318 and $45,356, respectively.

 

During the six months ended June 30, 2022 the Company’s CEO advanced the Company $202 and the Company purchased $12,090 worth of inventory from Ageless. Additionally, the Company received $26,000 worth of advances from Ageless to pay for operating expenses. The Company paid back $19,002 of the advances. The Company also issued 126,920 common shares to related parties for consulting services (see Note 6).

 

Note 6 - Equity

 

Common Stock

 

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

 

During the three months ended March 31, 2023, the Company issued 34,371,100 shares of common stock to Best shareholders in exchange for all of the shares of Best common stock (see Note 2) resulting in an increase in common stock of $3,437 and a decrease in additional paid-in-capital of $4,528.

 

During the three months ended June 30, 2023, the Company issued 480,000 common shares for cash proceeds of $120,000.

 

During the three months ended March 31, 2022, the Company issued 2,284,556 shares to third parties for consulting services valued at $4,050 and issued 126,920 shares to related parties for consulting services valued at $225.

 

During the three months ended June 30, 2022 there were no issuances of common stock.

 

As of June 30, 2023 and December 31, 2022, the Company had 40,312,600 and 5,461,500 shares of common stock issued and outstanding, respectfully.

 

Preferred Stock

 

On October 19, 2021, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing up to 5,000,000 shares of Preferred Stock, par value $0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted by the Board of Directors. On November 1, 2021, the Company filed a Certificate of Designation designating 1,000,000 shares of Preferred Stock as Series A Convertible Preferred Stock (the “Series A”). Each share of the Series A is convertible into three shares of the Company’s common stock at the holder's election, subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice.

 

During the six months ended June 30, 2023 and 2022 there were no issuances of preferred stock. As of June 30, 2023 and December 31, 2022, the Company had 140,000 shares of Series A Convertible Preferred Stock outstanding.

 

Note 7 - Subsequent Events

 

The Company has evaluated all events that occur after the balance sheet date through August 11, 2023, the date when the financial statements were available to be issued, to determine if they must be reported. Management of the Company determined that there are no material subsequent events to be disclosed other than those described below.

 

Subsequent to June 30, 2023, the Company received advances of $900 from related parties and made repayments of $26,600. On July 20, the Company issued 80,000 common shares for $20,000.

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding Forward Looking Statements

 

This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business, our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

 

The results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements include those described elsewhere in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under “Item 1A. – Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

 

Overview

 

We have limited operations since inception other than the expenditures related to running the Company, and we have generated minimal revenues and a net loss during the six months ended June 30, 2023, and is showing total liabilities in excess of total assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company is attempting to commence full-scale operations and generate sufficient revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations long-term. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.

 

Plan of Operation

 

On February 13, 2023, Nowtransit Inc. entered into the Exchange Agreement with Best 365 Labs Inc. (“Best”) and the shareholders of Best who collectively owned 9,588,000 shares of Best common stock, or 100% of the outstanding shares of Best common stock. The transaction consummated on March 10, 2023 (the “Closing”).

 

Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the shares of the Company’s common stock to be outstanding, in exchange for all of the shares of Best common stock held by Best shareholders. The transaction was accounted for as a reserve merger. Best was the accounting acquirer and Nowtransit the accounting acquiree. As such, the consolidated financial statements presented are the historical financial statements of Best with retroactive adjustments to reflect the equity of Nowtransit. Since Nowtransit was the legal acquirer, the resulting financial statements are in the name of Nowtransit.

 

During the next 12 month period, the Company will continue to market and sell clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels. Presently, the Company is marketing Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, EZ Safer Surface Cleaner, Be On-Guard.Brain Fog Support and ADHD 365 maximum strength brain support.

 

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Management’s discussion and analysis and results of operations are based upon our accompanying financial statements for the six and three months ended June 30, 2023, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Note 3. Summary of Significant Accounting Policies, to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, describes the significant accounting policies and methods used in the preparation of the Company’s financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

 

Results Of Operations

 

THREE MONTHS ENDED JUNE 30, 2023 COMPARED TO JUNE 30, 2022

 

Our net loss for the three months ended June 30, 2023 was $85,262, compared to a net loss of $1,878 during the three months ended June 30, 2022. The Company has generated revenue of $69,465 and $8,049 during the three months ended June 30, 2023 and 2022, respectively.  The increase over time is due to Company growth and increased sales and marketing efforts. The increase in net loss was due to an increase in general administrative expenses including professional fees in connection with the preparation of SEC reports, marketing and promotions and our completion of the reverse merger. Expenses incurred were general administrative expenses of $138,728 during the three months ended June 30, 2023, compared to $8,445 during the three months ended June 30, 2022.

 

SIX MONTHS ENDED JUNE 30, 2023 COMPARED TO JUNE 30, 2022

 

Our net loss for the six months ended June 30, 2023 was $155,978, compared to a net loss of $6,089 during the six months ended June 30, 2022. The Company has generated revenue of $101,802 and $8,328 during the three months ended June 30, 2023 and 2022, respectively. The increase in net loss was due to an increase in general administrative expenses including professional fees in connection with the preparation of SEC reports, marketing and promotions and our completion of the reverse merger. Expenses incurred were general administrative expenses of $231,035, during the six months ended June 30, 2023, compared to $8,595 during the six months ended June 30, 2022.

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of June 30, 2023, our total assets were $62,967, consisting of cash, accounts receivable, prepaid expenses, and inventory.

 

Cash Flows from Operating Activities

 

We have not generated positive cash flows from operating activities since inception. For the six months ended June 30, 2023, net cash flows used in operating activities was $181,007, consisting of our net loss of $155,978 offset by changes in operating activities of $25,029. For the six months ended June 30, 2022, net cash flows used in operating activities was $11,162, consisting of our net loss of $6,089 plus net changes in operating activities of $9,348, offset by stock issued for services of $4,275.

 

Cash Flows from Investing Activities

 

We have not engaged in any investing activities since our inception.

 

Cash Flows from Financing Activities

 

For the six months ended June 30, 2023 net cash flows provided by financing activities was $199,755, consisting of cash acquired in recapitalization of $8,793, advances from related parties of $180,574 offset by repayments to related parties of $109,612, and $120,000 of cash acquired for issuing common stock. For the six months ended June 30, 2022, net cash flows provided by financing activities was $19,290, consisting of $38,292 in advances from related parties offset by repayments to related parties of $19,002.

 

PLAN OF OPERATION AND FUNDING

 

Currently, the Company is in the process of offering a private placement to accredited investors to raise up to $1,000,000. Once the private placement is complete the Company will begin the process of preparing and filing Form 1-A with the SEC.

 

 

The Nowtransit management team plans to focus on gaining traction for its mental health and general wellness products. Best 365 Labs, Inc has filed for a provisional patent on its mental wellness, natural products which is an additional reason we plan to focus and grow this sector of the products. With the Global Mental Health Marketplace currently valued at $383.31 billion annually and with 41 million people holding a prescription for Adderall that the market conditions are idea for us to offer our natural substitute product options (which are also unique). Management believes with adequate advertising and marketing funds that substantial clients could be acquired in these categories.

 

Management believes that several current Adderall users would be open to a dietary supplement alternative, e.g., our ADHD 365 Tablets (www.365ADHD.com). In addition, we believe that the 1-14 Americans currently suffering brain fog will take a serious look at our Be-OnGuard Brain Fog Support (www.Mindfoghelp.com). In addition, we are marketing the product www.NattyAddy.com and believes it has immense potential especially with the college students.

 

To support and test our assumptions the current management team has been building introductory sales channels including Amazon as well as other direct vendors. Return on Ad Spend “ROAS” so far has been initially promising on these test channels, i.e., close to 3:1. Management believes that Google and Amazon sales could be substantially grown through additional advertising spends.

 

In addition, management is under an NDA but is exploring a health and mental wellness app that could offer very compelling data on our suite of products. The psychiatrist we are exploring this concept with has 40 plus years’ experience. As a management team our objective is to deliver unique products at very affordable prices to the masses that enrich and empower their lives.

 

Currently management is looking to raise $1 million dollars at $0.25 cents a share in a private placement for accredited investors. Management believes that these resources will place the company on a $10 million revenue trajectory. Once this raise is completed the plan is to raise an additional $6 million in capital through a REG A offering. Though no price on the REG A has been set it still has to be written up and cleared by the SEC, management’s initial plan is for those shares to be offered at $1.50 to $2 per share. The Company then plans to work to get the Company on a $25 million revenue trajectory and work toward a NASDAQ listing which is a management objective for mid-2024.

 

Currently, the Best 365 Labs Inc. suite of products are not drugs and not under the FDA. The products are considered Dietary Supplements and General Wellness products and are governed under the DSHEA. We do have a medical director who is a practicing and license with 40 years of experience and a Respiratory Therapist. We are not against prescription drugs we are for health, wellness, longevity and having people take ownership of their health and wellness. We our potential patent protection, uniqueness, and effectiveness especially in the mental health and wellness category management truly believes the opportunity for growth is immense. Further management believes that if they can secure the funding that the plan.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Going Concern

 

There is no historical financial information about us upon which to base an evaluation of our performance. We have minimal operations, cumulative losses, and have generated minimal revenues. Our business is subject to risks inherent in marketing products in a competitive market as we continue to sell clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels. Presently, the Company is marketing Be On-Guard Mouth Spray, Be On-Guard Nasal Spray,EZ, Safer Surface Cleaner, Be On-Guard Brain Fog Support and ADHD 365 maximum strength brain support, while also having limited capital resources and expecting possible cost overruns due to price and cost increases in services and products.

 

There can be no assurance that future financing will be available to us on acceptable terms or at all. If financing is not available on satisfactory terms as and when needed, we may be unable to commence, develop or expand our operations. Equity financing could result in additional dilution to existing stockholders.

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

As of June 30, 2023 (the “Evaluation Date”), the Company’s management evaluated, with participation of its principal executive officer, the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, the Company’s principal executive officer concluded that the Company’s disclosure controls and procedures were ineffective as of June 30, 2023.

 

Management assessed the effectiveness of its internal control over financial reporting as of the Evaluation Date based on criteria for effective internal control over financial reporting described in Internal Control—Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. The material weaknesses identified during management’s assessment were (i) a lack of sufficient internal accounting resources; (ii) a lack of segregation of duties to ensure adequate review of financial statement preparation, (iii) lack of an independent board of directors or audit committee, and (iv) lack of written documentation of our internal control policies and procedures. In light of these material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting at the Evaluation Date. We plan to rectify these weaknesses by establishing written policies and procedures for our internal control of financial reporting and hiring additional accounting personnel at such time as we raise sufficient capital to do so. There were no changes in controls during the quarter ended June 30, 2023.

 

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

 

Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds

 

On June 2, 2023, the Company issued 80,000 common shares of cash proceeds of $20,000.

 

On June 15, 2023, the Company issued 400,000 common shares for cash proceeds of $100,000.

 

On July 20, 2023, the Company issued 80,000 common shares for cash proceeds of $20,000. 

 

Item 3. Defaults Upon Senior Securities

 

Not applicable.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

Not applicable.

 

 

Item 6. Exhibits

 

Exhibit #

 

Exhibit Description

 

Incorporated By Reference

Filed or Furnished Herewith

 

 

 

 

Form

Date

Number

 

3.1(a)

 

Articles of Incorporation

 

S-1

11/4/2019

3.1

 

 

 

 

 

 

 

 

 

3.1(b)

 

Amendment to Articles of Incorporation

 

10-K

11/26/2021

3.1B

 

 

 

 

 

 

 

 

 

3.2

 

Bylaws

 

S-1

11/4/2019

3.2

 

 

 

 

 

 

 

 

 

10.1

 

Stock purchase agreement dated August 29, 2022*

 

 

 

 

Filed

 

 

 

 

 

 

 

 

10.2

 

Stock purchase Agreement dated October 19, 2022*

 

 

 

 

Filed

 

 

 

 

 

 

 

 

10.3

 

Stock purchase Agreement dated December 20, 2022

 

 

 

 

Filed

 

 

 

 

 

 

 

 

31.1

 

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)

 

 

 

 

Filed

 

 

 

 

 

 

 

 

32.1

 

Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002

 

 

 

 

Furnished**

 

 

 

 

 

 

 

 

101

 

Inline Interactive data files pursuant to Rule 405 of Regulation S-T

 

 

 

 

Filed

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

* Certain schedules, appendices and exhibits have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule, appendix and/or exhibit will be furnished supplementally to the Staff of the Securities and Exchange Commission upon request.

**This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Nowtransit Inc.

 

 

 

 

 

Dated: August 11, 2023

By:

/s/ Darren Lopez

 

 

 

Darren Lopez

Chief Executive Officer

(Principal Executive Officer)

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Darren Lopez

 

Principal Executive Officer and Director

 

August 11, 2023

Darren Lopez

 

 

 

 

 

17
NONE false --12-31 Q2 2023 0001784440 0001784440 2023-01-01 2023-06-30 0001784440 2023-08-08 0001784440 2023-06-30 0001784440 2022-12-31 0001784440 us-gaap:RelatedPartyMember 2023-06-30 0001784440 us-gaap:RelatedPartyMember 2022-12-31 0001784440 2023-04-01 2023-06-30 0001784440 2022-04-01 2022-06-30 0001784440 2022-01-01 2022-06-30 0001784440 us-gaap:PreferredStockMember 2021-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001784440 us-gaap:RetainedEarningsMember 2021-12-31 0001784440 2021-12-31 0001784440 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001784440 2022-01-01 2022-03-31 0001784440 us-gaap:RelatedPartyMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001784440 us-gaap:RelatedPartyMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001784440 us-gaap:RelatedPartyMember 2022-01-01 2022-03-31 0001784440 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001784440 us-gaap:PreferredStockMember 2022-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001784440 us-gaap:RetainedEarningsMember 2022-03-31 0001784440 2022-03-31 0001784440 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001784440 us-gaap:PreferredStockMember 2022-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001784440 us-gaap:RetainedEarningsMember 2022-06-30 0001784440 2022-06-30 0001784440 us-gaap:PreferredStockMember 2022-12-31 0001784440 us-gaap:CommonStockMember 2022-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001784440 us-gaap:RetainedEarningsMember 2022-12-31 0001784440 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001784440 2023-01-01 2023-03-31 0001784440 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001784440 us-gaap:PreferredStockMember 2023-03-31 0001784440 us-gaap:CommonStockMember 2023-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001784440 us-gaap:RetainedEarningsMember 2023-03-31 0001784440 2023-03-31 0001784440 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001784440 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001784440 us-gaap:PreferredStockMember 2023-06-30 0001784440 us-gaap:CommonStockMember 2023-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001784440 us-gaap:RetainedEarningsMember 2023-06-30 0001784440 notr:Best365LabsIncMember 2023-02-13 2023-02-13 0001784440 notr:Best365LabsIncMember 2023-02-13 0001784440 notr:Best365LabsIncMember 2023-03-10 2023-03-10 0001784440 notr:Best365LabsIncMember 2023-03-10 0001784440 notr:NowtransitMember 2023-01-01 2023-03-31 0001784440 srt:ProFormaMember 2023-01-01 2023-06-30 0001784440 2023-03-10 0001784440 srt:AffiliatedEntityMember notr:AgelessHoldingsLLCMember 2023-06-30 0001784440 notr:AgelessHoldingsLLCMember 2023-01-01 2023-06-30 0001784440 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-06-30 0001784440 notr:AgelessHoldingsLLCMember 2022-06-30 0001784440 notr:AgelessHoldingsLLCMember 2022-01-01 2022-06-30 0001784440 notr:Best365LabsIncMember 2023-01-01 2023-03-31 0001784440 us-gaap:SeriesAPreferredStockMember 2023-06-30 0001784440 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001784440 us-gaap:SubsequentEventMember 2023-07-01 2023-07-20 0001784440 us-gaap:SubsequentEventMember 2023-07-20 2023-07-20 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 10.1

 

STOCK PURCHASE AGREEMENT

 

THIS STOCK PURCHASE AGREEMENT (“Agreement”), dated as of August 29, 2022, is by and between Stock Loans Solutions, LLC, a Utah limited liability company (“Purchaser”), and Best 365 Labs, Inc., a Nevada corporation (“Company”) (individually a “Party” and collectively the “Parties”).

 

W I T N E S S E T H

 

WHEREAS, Company desires to raise capital for general corporate purposes;

 

WHEREAS, Company has offered for sale to Purchaser shares of common stock of Company (the “Shares”), representing 0.99% ownership of the Company, at an average purchase price of $0.53 per Share; and

 

WHEREAS, Company desires to sell to Purchaser, and Purchaser desires to purchase from Company, 94,000 Shares upon the terms and conditions set forth herein. NOW THEREFORE, in consideration of the promises and respective mutual agreements herein contained, it is agreed by and between the Parties hereto as follows:

 

ARTICLE 1

SALE AND PURCHASE OF THE SHARES

 

 

1.1

Sale of the Shares. Upon execution of this Agreement, subject to the terms and conditions herein set forth, and on the basis of the representations, warranties, and agreements herein contained, Company shall sell to Purchaser, and Purchaser shall purchase from Company, the Shares representing 0.99% ownership of the Company.

 

 

1.2

Instruments of Conveyance and Transfer. As soon as practicable after the full execution of this Agreement and receipt and clearing of the Purchase Price (as defined below), Company shall deliver a certificate or certificates representing the Shares of Company to Purchaser sufficient to transfer all right, title, and interest in the Shares to Purchaser.

 

 

1.3

Consideration and Payment for the Shares. In consideration for the Shares, Purchaser shall pay a total Purchase Price of $50,000 ($0.53 per share) (the “Purchase Price”).

 

 

1.4

The Closing. All funds accepted from the Investor will be immediately available to the Company upon Closing.

 

ARTICLE 2

REPRESENTATIONS AND COVENANTS OF COMPANY AND PURCHASER

 

2.1 Company hereby represents, warrants, and covenants that:

 

(a) The Company shall use the proceeds from the Purchase Price for general corporate purposes only and shall not use the Purchase Price proceeds, at any time, to lend money, give credit, or make advances to any officer, director, employee, or affiliate of the

Company.

 

(b) The Shares issued hereunder have been duly authorized by the appropriate corporate action of Company.

 

(c) Company shall transfer title, in and to the Shares to Purchaser free and clear of all liens, security interests, pledges, encumbrances, charges, restrictions, demands and claims, of any kind and nature whatsoever, whether direct or indirect or contingent.

 

(d) As soon as practicable after the Closing, Company shall deliver to Purchaser a certificate or certificates representing the Shares subject to no liens, security interests, pledges, encumbrances, charges, restrictions, demands or claims in any other party whatsoever, except as set forth in the legend on the certificate, which legend shall provide as follows:

 

THE SHARES (OR OTHER SECURITIES) REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS AVAILABLE.

 

 

 

 

(e) Purchaser acknowledges that the Shares are “restricted securities” (as such term is defined in Rule 144 promulgated under the Act (“Rule 144”), that the Shares will include the foregoing restrictive legend, and, except as otherwise set forth in this Agreement, that the Shares cannot be sold unless registered with the SEC and qualified by appropriate state securities regulators, or unless Purchaser obtains written consent from Company and otherwise complies with an exemption from such registration and qualification (including, without limitation, compliance with Rule 144).

 

(f) In order to induce Purchaser to enter into this Agreement, Company has agreed to grant to Purchaser certain rights as a shareholder, including but not limited to redemption rights, anti-dilution protection, registration rights, and participation rights, which are set forth in an Investor Rights Agreement between the Parties and which Investor Rights Agreement shall survive the closing of the transactions contemplated herein.

 

2.2 Purchaser represents and warrants to Company as follows:

 

(a) Purchaser has adequate means of providing for current needs and contingencies, has no need for liquidity in the investment, and is able to bear the economic risk of an investment in the Shares offered by Company of the size contemplated. Purchaser represents that Purchaser is able to bear the economic risk of the investment and at the present time could afford a complete loss of such investment. Purchaser has had a full opportunity to inspect the books and records of the Company and to make any and all inquiries of Company officers and directors regarding the Company and its business as Purchaser has deemed appropriate.

 

(b) Purchaser is an “Accredited Investor” as defined in Regulation D of the Act or Purchaser, either alone or with Purchaser’s professional advisers who are unaffiliated with, have no equity interest in, and are not compensated by Company or any affiliate or selling agent of Company, directly or indirectly, has sufficient knowledge and experience in financial and business matters that Purchaser is capable of evaluating the merits and risks of an investment in the Shares offered by Company and of making an informed investment decision with respect thereto and has the capacity to protect Purchaser’s own interests in connection with Purchaser’s proposed investment in the Shares.

 

(c) Purchaser is acquiring the Shares solely for Purchaser’s own account as principal, for investment purposes only and not with a view to the resale or distribution thereof, in whole or in part, and no other person or entity has a direct or indirect beneficial interest in such Shares.

 

(d) Purchaser will not sell or otherwise transfer the Shares without registration under the Act, or an exemption therefrom, and fully understands and agrees that Purchaser must bear the economic risk of Purchaser’s purchase for an indefinite period of time because, among other reasons, the Shares have not been registered under the Act or under the securities laws of any state and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Act and under the applicable securities laws of such states or unless an exemption from such registration is available.

 

ARTICLE 3

MISCELLANEOUS

 

3.1 Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties hereto with respect to the transactions contemplated hereby, and supersedes all prior agreements, arrangements, and understandings related to the subject matter hereof. No understanding, promise, inducement, statement of intention, representation, warranty, covenant, or condition, written or oral, express or implied, whether by statute or otherwise, has been made by any Party hereto which is not embodied in this Agreement or the written statements, certificates, or other documents delivered pursuant hereto or in connection with the transactions

contemplated hereby, and no Party hereto shall be bound by or liable for any alleged understanding, promise, inducement, statement, representation, warranty, covenant, or condition not so set forth.

 

3.2 Notices. Any notice, request, instruction, or other document required by the terms of this Agreement, or deemed by either of the Parties hereto to be desirable, to be given to either Party hereto shall be in writing and shall be given by personal delivery, overnight delivery, mailed by registered or certified mail, postage prepaid, with return receipt requested, or sent by electronic mail (with receipt confirmed) to the addresses of the Parties as follows:

To Purchaser: Stock Loan Solutions, LLC

Attn: Joe Thomas

6582 S. Big Cottonwood Canyon Rd., Suite 200

Salt Lake City, UT 84121

Email: joe@stockloansolutions.com

 

To Company: Best 365 Labs, Inc.

Attn: Darren Lopez

2722 S West Temple

Salt Lake City, Utah 84115

Email: darren@best365labs.com 

 

 

 

The persons and addresses set forth above may be changed from time to time by a notice sent as aforesaid. If notice is given by personal delivery or overnight delivery in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given at the time of such delivery provided a receipt is obtained from the recipient. If notice is given by mail in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given upon receipt and delivery or refusal. If notice is given by electronic mail transmission in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given at the time of delivery if during business hours, and if not during business hours, at the next business day following delivery, provided a confirmation is obtained by the sender.

 

3.3 Waiver and Amendment. Any term, provision, covenant, representation, warranty, or condition of this Agreement may be waived, but only by a written instrument signed by the Party entitled to the benefits thereof. The failure or delay of any Party at any time or times to require performance of any provision hereof, or to exercise its rights with respect to any provision hereof, shall in no manner operate as a waiver of or affect such Party’s right at a later time to enforce the same. No waiver by any Party of any condition, or of the breach of any term, provision, covenant, representation, or warranty contained in this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach or waiver of any other condition or of the breach of any other term, provision, covenant, representation, or warranty. No modification or amendment of this Agreement shall be valid and binding unless it be in writing and signed by all Parties hereto.

 

3.4 Choice of Law. This Agreement and the rights of the Parties hereunder shall be governed by and construed in accordance with the laws of the State of Utah including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws.

 

3.5 Jurisdiction. The Parties submit to the jurisdiction of the Courts of the County of Salt Lake, State of Utah or a Federal Court empaneled in the State of Utah for the resolution of all legal disputes arising under the terms of this Agreement, including, but not limited to, enforcement of any arbitration award.

 

3.6 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original hereof, but all of which, taken together, shall constitute one and the same agreement as of the date hereof. Any delivery of signature pages of counterparts by way of facsimile or by electronic transmittal of scanned images thereof shall constitute delivery hereof, in each case subject to appropriate customary confirmations in respect thereof by the signatory for the Party providing a facsimile or scanned image.

 

3.7 Attorneys’ Fees. Except as otherwise provided herein, if a dispute should arise between the parties including, but not limited to arbitration, the prevailing Party shall be reimbursed by the non-prevailing Party for all reasonable expenses incurred in resolving such dispute, including reasonable attorneys’ fees exclusive of such amount of attorneys’ fees as shall be a premium for result or for risk of loss under a contingency fee arrangement.

 

3.8 Taxes. Any income taxes required to be paid in connection with the payments due hereunder, shall be borne by the Party required to make such payment. Any withholding taxes in the nature of a tax on income shall be deducted from payments due, and the Party required to withhold such tax shall furnish to the Party receiving such payment all documentation necessary to prove the proper amount to withhold of such taxes and to prove payment to the tax authority of such required withholding.

 

3.9 Definition of “days.” When used herein, the term “days” refers to calendar days unless otherwise specified.

 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement, as of the date first written hereinabove.

 

COMPANY:

Best 365 Labs, Inc.,

a Nevada corporation

By: Darren Lopez

Its: CEO

 

PURCHASER:

Stock Loan Solutions, LLC,

a Utah limited liability company

By: Joe Thomas

Its: Managing Member

 

 

Exhibit 10.2

 

STOCK PURCHASE AGREEMENT

 

THIS STOCK PURCHASE AGREEMENT (“Agreement”), dated as of October 19, 2022, is by and between Stock Loans Solutions, LLC, a Utah limited liability company (“Purchaser”), and Best 365 Labs, Inc., a Nevada corporation (“Company”) (individually a “Party” and collectively the “Parties”).

 

W I T N E S S E T H

 

WHEREAS, Company desires to raise capital for general corporate purposes;

 

WHEREAS, Company has offered for sale to Purchaser shares of common stock of Company (the “Shares”), representing 0.98% ownership of the Company, at an average purchase price of $0.53 per Share; and

 

WHEREAS, Company desires to sell to Purchaser, and Purchaser desires to purchase from Company, 94,000 Shares upon the terms and conditions set forth herein. NOW THEREFORE, in consideration of the promises and respective mutual agreements herein contained, it is agreed by and between the Parties hereto as follows:

 

ARTICLE 1

SALE AND PURCHASE OF THE SHARES

 

 

1.1

Sale of the Shares. Upon execution of this Agreement, subject to the terms and conditions herein set forth, and on the basis of the representations, warranties, and agreements herein contained, Company shall sell to Purchaser, and Purchaser shall purchase from Company, the Shares representing 0.98% ownership of the Company.

 

 

1.2

Instruments of Conveyance and Transfer. As soon as practicable after the full execution of this Agreement and receipt and clearing of the Purchase Price (as defined below), Company shall deliver a certificate or certificates representing the Shares of Company to Purchaser sufficient to transfer all right, title, and interest in the Shares to Purchaser.

 

 

1.3

Consideration and Payment for the Shares. In consideration for the Shares, Purchaser shall pay a total Purchase Price of $50,000 ($0.53 per share) (the “Purchase Price”).

 

 

1.4

The Closing. All funds accepted from the Investor will be immediately available to the Company upon Closing.

 

ARTICLE 2

REPRESENTATIONS AND COVENANTS OF COMPANY AND PURCHASER

 

2.1 Company hereby represents, warrants, and covenants that:

 

(a) The Company shall use the proceeds from the Purchase Price for general corporate purposes only and shall not use the Purchase Price proceeds, at any time, to lend money, give credit, or make advances to any officer, director, employee, or affiliate of the

Company.

 

(b) The Shares issued hereunder have been duly authorized by the appropriate corporate action of Company.

 

(c) Company shall transfer title, in and to the Shares to Purchaser free and clear of all liens, security interests, pledges, encumbrances, charges, restrictions, demands and claims, of any kind and nature whatsoever, whether direct or indirect or contingent.

 

(d) As soon as practicable after the Closing, Company shall deliver to Purchaser a certificate or certificates representing the Shares subject to no liens, security interests, pledges, encumbrances, charges, restrictions, demands or claims in any other party whatsoever, except as set forth in the legend on the certificate, which legend shall provide as follows:

 

THE SHARES (OR OTHER SECURITIES) REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS AVAILABLE.

 

 

 

 

(e) Purchaser acknowledges that the Shares are “restricted securities” (as such term is defined in Rule 144 promulgated under the Act (“Rule 144”), that the Shares will include the foregoing restrictive legend, and, except as otherwise set forth in this Agreement, that the Shares cannot be sold unless registered with the SEC and qualified by appropriate state securities regulators, or unless Purchaser obtains written consent from Company and otherwise complies with an exemption from such registration and qualification (including, without limitation, compliance with Rule 144).

 

(f) In order to induce Purchaser to enter into this Agreement, Company has agreed to grant to Purchaser certain rights as a shareholder, including but not limited to redemption rights, anti-dilution protection, registration rights, and participation rights, which are set forth in an Investor Rights Agreement between the Parties and which Investor Rights Agreement shall survive the closing of the transactions contemplated herein.

 

2.2 Purchaser represents and warrants to Company as follows:

 

(a) Purchaser has adequate means of providing for current needs and contingencies, has no need for liquidity in the investment, and is able to bear the economic risk of an investment in the Shares offered by Company of the size contemplated. Purchaser represents that Purchaser is able to bear the economic risk of the investment and at the present time could afford a complete loss of such investment. Purchaser has had a full opportunity to inspect the books and records of the Company and to make any and all inquiries of Company officers and directors regarding the Company and its business as Purchaser has deemed appropriate.

 

(b) Purchaser is an “Accredited Investor” as defined in Regulation D of the Act or Purchaser, either alone or with Purchaser’s professional advisers who are unaffiliated with, have no equity interest in, and are not compensated by Company or any affiliate or selling agent of Company, directly or indirectly, has sufficient knowledge and experience in financial and business matters that Purchaser is capable of evaluating the merits and risks of an investment in the Shares offered by Company and of making an informed investment decision with respect thereto and has the capacity to protect Purchaser’s own interests in connection with Purchaser’s proposed investment in the Shares.

 

(c) Purchaser is acquiring the Shares solely for Purchaser’s own account as principal, for investment purposes only and not with a view to the resale or distribution thereof, in whole or in part, and no other person or entity has a direct or indirect beneficial interest in such Shares.

 

(d) Purchaser will not sell or otherwise transfer the Shares without registration under the Act, or an exemption therefrom, and fully understands and agrees that Purchaser must bear the economic risk of Purchaser’s purchase for an indefinite period of time because, among other reasons, the Shares have not been registered under the Act or under the securities laws of any state and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Act and under the applicable securities laws of such states or unless an exemption from such registration is available.

 

ARTICLE 3

MISCELLANEOUS

 

3.1 Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties hereto with respect to the transactions contemplated hereby, and supersedes all prior agreements, arrangements, and understandings related to the subject matter hereof. No understanding, promise, inducement, statement of intention, representation, warranty, covenant, or condition, written or oral, express or implied, whether by statute or otherwise, has been made by any Party hereto which is not embodied in this Agreement or the written statements, certificates, or other documents delivered pursuant hereto or in connection with the transactions

contemplated hereby, and no Party hereto shall be bound by or liable for any alleged understanding, promise, inducement, statement, representation, warranty, covenant, or condition not so set forth.

 

3.2 Notices. Any notice, request, instruction, or other document required by the terms of this Agreement, or deemed by either of the Parties hereto to be desirable, to be given to either Party hereto shall be in writing and shall be given by personal delivery, overnight delivery, mailed by registered or certified mail, postage prepaid, with return receipt requested, or sent by electronic mail (with receipt confirmed) to the addresses of the Parties as follows:

To Purchaser: Stock Loan Solutions, LLC

Attn: Joe Thomas

6582 S. Big Cottonwood Canyon Rd., Suite 200

Salt Lake City, UT 84121

Email: joe@stockloansolutions.com

 

To Company: Best 365 Labs, Inc.

Attn: Darren Lopez

2722 S West Temple

Salt Lake City, Utah 84115

Email: darren@best365labs.com 

 

 

 

The persons and addresses set forth above may be changed from time to time by a notice sent as aforesaid. If notice is given by personal delivery or overnight delivery in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given at the time of such delivery provided a receipt is obtained from the recipient. If notice is given by mail in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given upon receipt and delivery or refusal. If notice is given by electronic mail transmission in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given at the time of delivery if during business hours, and if not during business hours, at the next business day following delivery, provided a confirmation is obtained by the sender.

 

3.3 Waiver and Amendment. Any term, provision, covenant, representation, warranty, or condition of this Agreement may be waived, but only by a written instrument signed by the Party entitled to the benefits thereof. The failure or delay of any Party at any time or times to require performance of any provision hereof, or to exercise its rights with respect to any provision hereof, shall in no manner operate as a waiver of or affect such Party’s right at a later time to enforce the same. No waiver by any Party of any condition, or of the breach of any term, provision, covenant, representation, or warranty contained in this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach or waiver of any other condition or of the breach of any other term, provision, covenant, representation, or warranty. No modification or amendment of this Agreement shall be valid and binding unless it be in writing and signed by all Parties hereto.

 

3.4 Choice of Law. This Agreement and the rights of the Parties hereunder shall be governed by and construed in accordance with the laws of the State of Utah including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws.

 

3.5 Jurisdiction. The Parties submit to the jurisdiction of the Courts of the County of Salt Lake, State of Utah or a Federal Court empaneled in the State of Utah for the resolution of all legal disputes arising under the terms of this Agreement, including, but not limited to, enforcement of any arbitration award.

 

3.6 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original hereof, but all of which, taken together, shall constitute one and the same agreement as of the date hereof. Any delivery of signature pages of counterparts by way of facsimile or by electronic transmittal of scanned images thereof shall constitute delivery hereof, in each case subject to appropriate customary confirmations in respect thereof by the signatory for the Party providing a facsimile or scanned image.

 

3.7 Attorneys’ Fees. Except as otherwise provided herein, if a dispute should arise between the parties including, but not limited to arbitration, the prevailing Party shall be reimbursed by the non-prevailing Party for all reasonable expenses incurred in resolving such dispute, including reasonable attorneys’ fees exclusive of such amount of attorneys’ fees as shall be a premium for result or for risk of loss under a contingency fee arrangement.

 

3.8 Taxes. Any income taxes required to be paid in connection with the payments due hereunder, shall be borne by the Party required to make such payment. Any withholding taxes in the nature of a tax on income shall be deducted from payments due, and the Party required to withhold such tax shall furnish to the Party receiving such payment all documentation necessary to prove the proper amount to withhold of such taxes and to prove payment to the tax authority of such required withholding.

 

3.9 Definition of “days.” When used herein, the term “days” refers to calendar days unless otherwise specified.

 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement, as of the date first written hereinabove.

 

COMPANY:

Best 365 Labs, Inc.,

a Nevada corporation

By: Darren Lopez

Its: CEO

 

PURCHASER:

Stock Loan Solutions, LLC,

a Utah limited liability company

By: Joe Thomas

Its: Managing Member

 

 

 

Exhibit 10.3

 

 

STOCK PURCHASE AGREEMENT

 

THIS STOCK PURCHASE AGREEMENT (“Agreement”), dated as of December 20, 2022, is by and between Stock Loans Solutions, LLC, a Utah limited liability company (“Purchaser”), and Best 365 Labs, Inc., a Nevada corporation (“Company”) (individually a “Party” and collectively the “Parties”).

 

W I T N E S S E T H

 

WHEREAS, Company desires to raise capital for general corporate purposes;

 

WHEREAS, Company has offered for sale to Purchaser shares of common stock of Company (the “Shares”), representing 0.98% ownership of the Company, at an average purchase price of $0.5262 per Share; and

 

WHEREAS, Company desires to sell to Purchaser, and Purchaser desires to purchase from Company, 94.000 Shares upon the terms and conditions set forth herein. NOW THEREFORE, in consideration of the promises and respective mutual agreements herein contained, it is agreed by and between the Parties hereto as follows:

 

ARTICLE 1

SALE AND PURCHASE OF THE SHARES

 

 

1.1

Sale of the Shares. Upon execution of this Agreement, subject to the terms and conditions herein set forth, and on the basis of the representations, warranties, and agreements herein contained, Company shall sell to Purchaser, and Purchaser shall purchase from Company, the Shares representing 0.97% ownership of the Company.

 

 

1.2

Instruments of Conveyance and Transfer. As soon as practicable after the full execution of this Agreement and receipt and clearing of the Purchase Price (as defined below), Company shall deliver a certificate or certificates representing the Shares of Company to Purchaser sufficient to transfer all right, title, and interest in the Shares to Purchaser.

 

 

1.3

Consideration and Payment for the Shares. In consideration for the Shares, Purchaser shall pay a total Purchase Price of $50,000 ($0.5262 per share) (the “Purchase Price”).

 

 

1.4

The Closing. All funds accepted from the Investor will be immediately available to the Company upon Closing.

 

ARTICLE 2

REPRESENTATIONS AND COVENANTS OF COMPANY AND PURCHASER

 

2.1 Company hereby represents, warrants, and covenants that:

 

(a) The Company shall use the proceeds from the Purchase Price for general corporate purposes only and shall not use the Purchase Price proceeds, at any time, to lend money, give credit, or make advances to any officer, director, employee, or affiliate of the

Company.

 

(b) The Shares issued hereunder have been duly authorized by the appropriate corporate action of Company.

 

(c) Company shall transfer title, in and to the Shares to Purchaser free and clear of all liens, security interests, pledges, encumbrances, charges, restrictions, demands and claims, of any kind and nature whatsoever, whether direct or indirect or contingent.

 

(d) As soon as practicable after the Closing, Company shall deliver to Purchaser a certificate or certificates representing the Shares subject to no liens, security interests, pledges, encumbrances, charges, restrictions, demands or claims in any other party whatsoever, except as set forth in the legend on the certificate, which legend shall provide as follows:

 

THE SHARES (OR OTHER SECURITIES) REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS AVAILABLE.

 

 

 

 

(e) Purchaser acknowledges that the Shares are “restricted securities” (as such term is defined in Rule 144 promulgated under the Act (“Rule 144”), that the Shares will include the foregoing restrictive legend, and, except as otherwise set forth in this Agreement, that the Shares cannot be sold unless registered with the SEC and qualified by appropriate state securities regulators, or unless Purchaser obtains written consent from Company and otherwise complies with an exemption from such registration and qualification (including, without limitation, compliance with Rule 144).

 

(f) In order to induce Purchaser to enter into this Agreement, Company has agreed to grant to Purchaser certain rights as a shareholder, including but not limited to redemption rights, anti-dilution protection, registration rights, and participation rights, which are set forth in an Investor Rights Agreement between the Parties and which Investor Rights Agreement shall survive the closing of the transactions contemplated herein.

 

2.2 Purchaser represents and warrants to Company as follows:

 

(a) Purchaser has adequate means of providing for current needs and contingencies, has no need for liquidity in the investment, and is able to bear the economic risk of an investment in the Shares offered by Company of the size contemplated. Purchaser represents that Purchaser is able to bear the economic risk of the investment and at the present time could afford a complete loss of such investment. Purchaser has had a full opportunity to inspect the books and records of the Company and to make any and all inquiries of Company officers and directors regarding the Company and its business as Purchaser has deemed appropriate.

 

(b) Purchaser is an “Accredited Investor” as defined in Regulation D of the Act or Purchaser, either alone or with Purchaser’s professional advisers who are unaffiliated with, have no equity interest in, and are not compensated by Company or any affiliate or selling agent of Company, directly or indirectly, has sufficient knowledge and experience in financial and business matters that Purchaser is capable of evaluating the merits and risks of an investment in the Shares offered by Company and of making an informed investment decision with respect thereto and has the capacity to protect Purchaser’s own interests in connection with Purchaser’s proposed investment in the Shares.

 

(c) Purchaser is acquiring the Shares solely for Purchaser’s own account as principal, for investment purposes only and not with a view to the resale or distribution thereof, in whole or in part, and no other person or entity has a direct or indirect beneficial interest in such Shares.

 

(d) Purchaser will not sell or otherwise transfer the Shares without registration under the Act, or an exemption therefrom, and fully understands and agrees that Purchaser must bear the economic risk of Purchaser’s purchase for an indefinite period of time because, among other reasons, the Shares have not been registered under the Act or under the securities laws of any state and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Act and under the applicable securities laws of such states or unless an exemption from such registration is available.

 

ARTICLE 3

MISCELLANEOUS

 

3.1 Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties hereto with respect to the transactions contemplated hereby, and supersedes all prior agreements, arrangements, and understandings related to the subject matter hereof. No understanding, promise, inducement, statement of intention, representation, warranty, covenant, or condition, written or oral, express or implied, whether by statute or otherwise, has been made by any Party hereto which is not embodied in this Agreement or the written statements, certificates, or other documents delivered pursuant hereto or in connection with the transactions

contemplated hereby, and no Party hereto shall be bound by or liable for any alleged understanding, promise, inducement, statement, representation, warranty, covenant, or condition not so set forth.

 

3.2 Notices. Any notice, request, instruction, or other document required by the terms of this Agreement, or deemed by either of the Parties hereto to be desirable, to be given to either Party hereto shall be in writing and shall be given by personal delivery, overnight delivery, mailed by registered or certified mail, postage prepaid, with return receipt requested, or sent by electronic mail (with receipt confirmed) to the addresses of the Parties as follows:

To Purchaser: Stock Loan Solutions, LLC

Attn: Joe Thomas

6582 S. Big Cottonwood Canyon Rd., Suite 200

Salt Lake City, UT 84121

Email: joe@stockloansolutions.com

 

To Company: Best 365 Labs, Inc.

Attn: Darren Lopez

2722 S West Temple

Salt Lake City, Utah 84115

Email: darren@best365labs.com 

 

 

 

 

The persons and addresses set forth above may be changed from time to time by a notice sent as aforesaid. If notice is given by personal delivery or overnight delivery in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given at the time of such delivery provided a receipt is obtained from the recipient. If notice is given by mail in

accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given upon receipt and delivery or refusal. If notice is given by electronic mail transmission in accordance with the provisions of this Section 3.2, such notice shall be conclusively deemed given at the time of delivery if during business hours, and if not during business hours, at the next business day following delivery, provided a confirmation is obtained by the sender.

 

3.3 Waiver and Amendment. Any term, provision, covenant, representation, warranty, or condition of this Agreement may be waived, but only by a written instrument signed by the Party entitled to the benefits thereof. The failure or delay of any Party at any time or times to require performance of any provision hereof, or to exercise its rights with respect to any provision hereof, shall in no manner operate as a waiver of or affect such Party’s right at a later time to enforce the same. No waiver by any Party of any condition, or of the breach of any term, provision, covenant, representation, or warranty contained in this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach or waiver of any other condition or of the breach of any other term, provision, covenant, representation, or warranty. No modification or amendment of this Agreement shall be valid and binding unless it be in writing and signed by all Parties hereto.

 

3.4 Choice of Law. This Agreement and the rights of the Parties hereunder shall be governed by and construed in accordance with the laws of the State of Utah including all matters of construction, validity, performance, and enforcement and without giving effect to the principles of conflict of laws.

 

3.5 Jurisdiction. The Parties submit to the jurisdiction of the Courts of the County of Salt Lake, State of Utah or a Federal Court empaneled in the State of Utah for the resolution of all legal disputes arising under the terms of this Agreement, including, but not limited to, enforcement of any arbitration award.

 

3.6 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original hereof, but all of which, taken together, shall constitute one and the same agreement as of the date hereof. Any delivery of signature pages of counterparts by way of facsimile or by electronic transmittal of scanned images thereof shall constitute delivery hereof, in each case subject to appropriate customary confirmations in respect thereof by the signatory for the Party providing a facsimile or scanned image.

 

3.7 Attorneys’ Fees. Except as otherwise provided herein, if a dispute should arise between the parties including, but not limited to arbitration, the prevailing Party shall be reimbursed by the non-prevailing Party for all reasonable expenses incurred in resolving such dispute, including reasonable attorneys’ fees exclusive of such amount of attorneys’ fees as shall be a premium for result or for risk of loss under a contingency fee arrangement.

 

3.8 Taxes. Any income taxes required to be paid in connection with the payments due hereunder, shall be borne by the Party required to make such payment. Any withholding taxes in the nature of a tax on income shall be deducted from payments due, and the Party required to withhold such tax shall furnish to the Party receiving such payment all documentation necessary to prove the proper amount to withhold of such taxes and to prove payment to the tax authority of such required withholding.

 

3.9 Definition of “days.” When used herein, the term “days” refers to calendar days unless otherwise specified.

 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement, as of the date first written hereinabove.

 

COMPANY:

Best 365 Labs, Inc.,

a Nevada corporation

By: Darren Lopez

Its: CEO

 

PURCHASER:

Stock Loan Solutions, LLC,

a Utah limited liability company

By: Joe Thomas

Its: Managing Member

 

 

 

 

 

2722 S West Temple

Salt Lake City, UT 84115

Email: darren@best365labs.com

Attention: Darren Lopez, CEO

 

To the Purchaser: The address set forth on the Purchaser’s signature page attached hereto or to such other address as any of them, by notice to the other may designate from time to time. The transmission confirmation receipt from the sender’s facsimile machine shall be evidence of successful facsimile delivery. Time shall be counted from the date of transmission.

 

13. Attorneys Fees. In the event that there is any controversy or claim arising out of or relating to this Agreement, or to the interpretation, breach or enforcement thereof, and any action or arbitration proceeding is commenced to enforce the provisions of this Agreement, the prevailing party shall be entitled to a reasonable attorney’s fee, including the fees on appeal, costs and expenses.

 

14. Governing Law; Exclusive Jurisdiction. This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether relating to its execution, its validity, the obligations provided herein or performance shall be governed or interpreted according to the internal laws of the State of New York without regard to choice of law considerations. Any action brought by either Party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state or federal courts located in New York County, New York. The Parties hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.

 

15. Oral Evidence. This Agreement constitutes the entire Agreement between the parties and supersedes all prior oral and written agreements between the parties hereto with respect to the subject matter hereof. Neither this Agreement nor any provision hereof may be changed, waived, discharged or terminated orally, except by a statement in writing signed by the party or parties against which enforcement or the change, waiver discharge or termination is sought.

 

16. Assignment. No Party hereto shall assign its rights or obligations under this Agreement without the prior written consent of the other Party.

 

17. Section Headings. Section headings herein have been inserted for reference only and shall not be deemed to limit or otherwise affect, in any matter, or be deemed to interpret in whole or in part any of the terms or provisions of this Agreement.

 

[Signature Pages Follow]

 

 

 

 

 

 

 

 

IN WITNESS WHEREOF the parties hereto have set their hand and seals as of the above date.

 

COMPANY:

 

Nowtransit Inc.

 

 

By: /s/ Darren Lopez                                   

Name: Darren Lopez

Title: CEO

 

 

 

 

 

 

 

 

[SIGNATURE PAGE FOR PURCHASERS FOLLOWS]

 

 

 

 

[PURCHASER SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT]

 

IN WITNESS WHEREOF, the undersigned have caused this Stock Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

 

PURCHASER:

 

SLS Group LLC

 

 

By: /s/ Joe Thomas                          

Name: Joe Thomas

Title: President

Number of Shares: 282,000

Total Purchase Price: $150,000

 

Address for Notice:

 

Prime Services Group

4580 Thousand Oaks Drive

Salt Lake City, UT 84124

 

Email: jdtprimeservicesgroup@gmail.com

Attention: Joe Thomas

 

 

 

 

EXHIBIT B

 

TO STOCK PURCHASE AGREEMENT

 

Accredited Investor Definition

 

For Individual Investors Only:

 

 

1.

I had individual income in excess of $200,000 in each of the two most recent years or joint income with my spouse or Spousal Equivalent1 in excess of $300,000 in each of those years and have a reasonable expectation of reaching the same income level in the current year;

 

 

2.

I am a natural person whose individual net worth, or joint net worth2 with my spouse or Spousal Equivalent, exceeds $1,000,000. “Net worth” means the excess of total assets at fair market value (including personal and real property, but excluding the estimated fair market value of a person’s primary home) over total liabilities. “Total liabilities” excludes any mortgage on the primary home in an amount of up to the home’s estimated fair market value as long as the mortgage was incurred more than 60 days before the securities are purchased, but includes (i) any mortgage amount in excess of the home's fair market value and (ii) any mortgage amount that was borrowed during the 60-day period before the closing date for the sale of securities for the purpose of investing in the securities.

 

 

3.

I am a director, executive officer3 or general partner of Nowtransit Inc. (the “Company”) or a general partner of the general partner of the Company.

 

 

4.

I hold one of the following licenses in good standing: General Securities Representative license (Series 7), the Private Securities Offerings Representative license (Series 82), or the Investment Adviser Representative license (Series 65).

 

 

5.

I am a “knowledgeable employee,” as defined in rule 3c5(a)(4) under the Investment Company Act of 1940, of the issuer of the securities being offered or sold where the issuer would be an investment company, as defined in section 3 of such act, but for the exclusion provided by either section 3(c)(1) or section 3(c)(7) of such act.

 

For Entities:

 

 

1.

All of the beneficial equity owners of the undersigned qualify as accredited individual investors;

 

 


1 “Spousal equivalent” means a cohabitant occupying a relationship generally equivalent to that of a spouse.

2 “Joint net worth” can be the aggregate net worth of a person and spouse or spousal equivalent; assets do not need to be held jointly to be included in the calculation.

3 “Executive officer” means the president; any vice president in charge of a principal business unit, division or function, such as sales, administration or finance; or any other person or persons who perform(s) similar policymaking functions for the Company.)

 

 

 

 

2.

The undersigned is a bank as defined in Section 3(a)(2) of the Securities Act of 1933 (the “Securities Act”), or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity;

 

 

3.

The undersigned is a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934;

 

 

4.

The undersigned is an investment adviser registered pursuant to Section 203 of the Investment Advisers Act of 1940 or registered pursuant to the laws of a state;

 

 

5.

The undersigned is an investment adviser relying on the exemption from registering with the Commission under Section 203(l) or (m) of the Investment Advisers Act of 1940;

 

 

6.

The undersigned is an insurance company as defined in Section 2(a)(13) of the 1933 Act;

 

 

7.

The undersigned is an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that act;

 

 

8.

The undersigned is a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958;

 

 

9.

The undersigned is a Rural Business Investment Company as defined in Section 384A of the Consolidated Farm and Rural Development Act;

 

 

10.

The undersigned is a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

 

11.

The undersigned is an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974 and:

 

 

a.

the investment decision is made by a plan fiduciary, as defined therein, in Section 3(21), which is either a bank, savings and loan association, insurance company, or registered investment adviser; or

 

 

b.

the employee benefit plan has total assets in excess of $5,000,000; or

 

 

c.

the plan is a self-directed plan with investment decisions made solely by persons who are “accredited investors” as defined therein.

 

 

12.

The undersigned is a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 

 

13.

The undersigned has total assets in excess of $5,000,000, was not formed for the specific purpose of acquiring the securities offered and is one or more of the following:

 

 

 

 

 

a.

an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986;

 

 

b.

corporation,

 

 

c.

Massachusetts or similar business trust,

 

 

d.

partnership, or

 

 

e.

limited liability company,

 

 

14.

The undersigned is a trust with total assets exceeding $5,000,000, which was not formed for the specific purpose of acquiring the securities offered and whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the investment in the securities offered.

 

 

15.

The undersigned is an entity, of a type not listed above, not formed for the specific purpose of acquiring the securities offered, owning investments in excess of $5,000,000.

 

 

16.

The undersigned is a “family office,” as defined in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940: (i) with assets under management in excess of $5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment.

 

The undersigned is a “family client,” as defined in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940), of a family office meeting the requirements in the Section 16 above and whose prospective investment in the issuer is directed by such family office pursuant to Section 16(iii).

 

 

Exhibit 31.1

 

Certification of the Principal Executive Officer

 

I, Darren Lopez, Chief Executive Officer, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Nowtransit Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal three months (the registrant’s fourth fiscal three months in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 11, 2023

By:

/s/ Darren Lopez

 

 

 

Darren Lopez

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Nowtransit Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Darren Lopez, Principal Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that, to the best of my knowledge:

 

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 11, 2023

By:

/s/ Darren Lopez

 

 

 

Darren Lopez

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

(Principal Financial Officer)

 

 

 

 

 

 
v3.23.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 08, 2023
Document Information Line Items    
Entity Registrant Name NOWTRANSIT INC.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   40,392,600
Amendment Flag false  
Entity Central Index Key 0001784440  
Entity Current Reporting Status No  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Jun. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period true  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 333-234487  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 98-1498782  
Entity Address, Address Line One 2722 South West Temple  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84115  
City Area Code (801)  
Local Phone Number 949-0791  
Title of 12(b) Security None  
No Trading Symbol Flag true  
Security Exchange Name NONE  
Entity Interactive Data Current Yes  
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current Assets    
Cash and cash equivalents $ 30,317 $ 11,569
Accounts receivable, net 15,820 7,761
Inventory 15,830 12,278
Prepaid Expenses 1,000 0
Total current assets 62,967 31,608
Total Assets 62,967 31,608
Current Liabilities    
Accounts payable 901 3,435
STOCKHOLDERS' EQUITY (DEFICIT)    
Preferred stock: $0.0001 par value, 140,000 shares authorized; 140,000 shares issued and outstanding at June 30, 2023 and December 31, 2022 14 14
Common stock: $0.0001 par value, 75,000,000 shares authorized; 40,312,600 and 5,461,500 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 4,031 546
Additional paid-in capital 274,264 158,840
Accumulated deficit (332,561) (176,583)
Total stockholders' equity (deficit) (54,252) (17,183)
Total Liabilities and Stockholders' Equity (Deficit) 62,967 31,608
Related Party [Member]    
Current Liabilities    
Due to related parties 116,318 45,356
Total current liabilities $ 117,219 $ 48,791
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares issued 140,000 140,000
Preferred stock, shares outstanding 140,000 140,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares issued 40,312,600 5,461,500
Common stock, shares outstanding 40,312,600 5,461,500
Common stock, shares authorized 75,000,000 75,000,000
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenues $ 69,465 $ 8,049 $ 101,802 $ 8,328
Cost of goods sold (9,499) (982) (14,245) (1,047)
Gross profit 59,966 7,067 87,557 7,281
Operating Expenses:        
General and administrative expenses 138,728 8,445 231,035 8,595
Consulting fees 6,500 500 12,500 4,775
Total Operating Expenses 145,228 8,945 243,535 13,370
Loss from Operations (85,262) (1,878) (155,978) (6,089)
Net loss $ (85,262) $ (1,878) $ (155,978) $ (6,089)
Net loss per common share - basic and diluted (in Dollars per share) $ (0.01) $ 0 $ (0.01) $ 0
Weighted average common shares outstanding - basic and diluted (in Shares) 39,841,872 9,400,000 26,775,330 7,274,309
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Related Party [Member]
Preferred Stock [Member]
Related Party [Member]
Additional Paid-in Capital [Member]
Related Party [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Common Stock [Member]
Total
Balance at Dec. 31, 2021       $ 289 $ 4,836 $ (6,133)   $ (1,008)
Balance (in Shares) at Dec. 31, 2021       2,890,951        
Common shares issued for services $ 13 $ 212 $ 225 $ 228 3,822     $ 4,050
Common shares issued for services (in Shares) 126,920   126,920 2,284,556       2,284,556
Net loss           (4,211)   $ (4,211)
Balance at Mar. 31, 2022       $ 530 8,870 (10,344)   (944)
Balance (in Shares) at Mar. 31, 2022       5,302,427        
Balance at Dec. 31, 2021       $ 289 4,836 (6,133)   (1,008)
Balance (in Shares) at Dec. 31, 2021       2,890,951        
Net loss               (6,089)
Balance at Jun. 30, 2022       $ 530 8,870 (12,222)   (2,822)
Balance (in Shares) at Jun. 30, 2022       5,302,427        
Balance at Mar. 31, 2022       $ 530 8,870 (10,344)   (944)
Balance (in Shares) at Mar. 31, 2022       5,302,427        
Net loss           (1,878)   (1,878)
Balance at Jun. 30, 2022       $ 530 8,870 (12,222)   (2,822)
Balance (in Shares) at Jun. 30, 2022       5,302,427        
Balance at Dec. 31, 2022       $ 546 158,840 (176,583) $ 14 (17,183)
Balance (in Shares) at Dec. 31, 2022       5,461,500     140,000  
Recapitalization March 10, 2023       $ 3,437 (4,528)     $ (1,091)
Recapitalization March 10, 2023 (in Shares)       34,371,100       34,371,100
Net loss           (70,716)   $ (70,716)
Balance at Mar. 31, 2023       $ 3,983 154,312 (247,299) $ 14 (88,990)
Balance (in Shares) at Mar. 31, 2023       39,832,600     140,000  
Balance at Dec. 31, 2022       $ 546 158,840 (176,583) $ 14 (17,183)
Balance (in Shares) at Dec. 31, 2022       5,461,500     140,000  
Net loss               (155,978)
Balance at Jun. 30, 2023       $ 4,031 274,264 (332,561) $ 14 (54,252)
Balance (in Shares) at Jun. 30, 2023       40,312,600     140,000  
Balance at Mar. 31, 2023       $ 3,983 154,312 (247,299) $ 14 (88,990)
Balance (in Shares) at Mar. 31, 2023       39,832,600     140,000  
Common shares issued for cash       $ 48 119,952     $ 120,000
Common shares issued for cash (in Shares)       480,000       480,000
Net loss           (85,262)   $ (85,262)
Balance at Jun. 30, 2023       $ 4,031 $ 274,264 $ (332,561) $ 14 $ (54,252)
Balance (in Shares) at Jun. 30, 2023       40,312,600     140,000  
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flows From Operating Activities    
Net loss $ (155,978) $ (6,089)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock issued to related parties for services 0 225
Stock issued for services 0 4,050
Changes in operating activities:    
Accounts receivable (8,059) (772)
Inventory (3,552) (9,828)
Prepaid expenses (1,000)  
Accounts payable (12,418) 1,252
Net Cash Used in Operating Activities (181,007) (11,162)
Cash Flows From Investing Activities 0 0
Cash Flows From Financing Activities    
Advances from related parties 180,574 38,292
Repayment to related parties (109,612) (19,002)
Cash acquired in recapitalization 8,793 0
Stock issued for cash 120,000 0
Net Cash Provided by Financing Activities 199,755 19,290
Net Increase in Cash 18,748 8,128
Cash at Beginning of Period 11,569 100
Cash at End of Period 30,317 8,228
Supplemental Cash Flow Information:    
Cash paid for interest 0 0
Cash paid for income taxes $ 0 $ 0
v3.23.2
Nature of Organization
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Business Description and Basis of Presentation [Text Block]

Note 1 - Nature of Organization

 

Nowtransit Inc. (the “Company,” “us,” “we,” “Nowtransit”) was incorporated in the State of Nevada on July 8, 2019. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. (“Best”), a Nevada corporation, wherein we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company (see Note 2).

 

Best was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels. Presently, the Company is selling Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, Be On-Guard Brain Fog Support, ADHD 365 maximum brain support, and EZ Safer Surface Cleaner.

v3.23.2
Reorganization & Recapitalization
6 Months Ended
Jun. 30, 2023
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block]

Note 2 - Reorganization & Recapitalization

 

On February 13, 2023, Nowtransit entered into a Share Exchange Agreement with Best and the shareholders of Best who collectively owned 9,588,000 shares of Best common stock, or 100% of the outstanding shares of Best common stock. The transaction consummated on March 10, 2023 (the “Closing”).

 

Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock (see Note 6), representing approximately 85.39% of the shares of the Company’s common stock to be outstanding, in exchange for all of the shares of Best common stock held by Best shareholders. The transaction was accounted for as a reserve merger by Nowtransit and resulted in a recapitalization with Best being the accounting acquirer and Nowtransit being the accounting acquiree. As such, the consolidated financial statements presented are the historical financial statements of Best with retroactive adjustments to reflect the equity of Nowtransit, and the operations of Nowtransit from March 10, 2023, the effective date of the merger. Since Nowtransit was the legal acquirer, the resulting financial statements are in the name of Nowtransit. All share and per share information in the accompanying condensed consolidated financial statements and footnotes have been retroactively restated to reflect the recapitalization.

 

The following table summarizes the assets acquired and the liabilities assumed at the acquisition date of March 10, 2023:

 

Cash

  $ 8,793  

Accounts Payable

    (8,870

)

Credit Card Liability

    (1,014

)

Net Assets (Liabilities) Assumed

  $ (1,091

)

 

During the three months ended March 31, 2023 the Company reported $0 in revenue and $5,295 in expenses for the accounting acquiree (Nowtransit) since the acquisition date (March 10, 2023). Had Nowtransit and Best been combined since January 1, 2023 they would have reported revenues of $32,337, gross profit of $27,591, total operating expenses of $117,417, and a net loss of $89,826.

v3.23.2
Going Concern
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Substantial Doubt about Going Concern [Text Block]

Note 3 - Going Concern

 

The condensed consolidated financial statements have been prepared on a going concern basis which assumes the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

 

As reflected in the condensed consolidated financial statements, the Company had minimal revenues and a net loss during the six months ended June 30, 2023 and is showing total liabilities in excess of total assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company is attempting to commence full-scale operations and generate sufficient revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations long-term. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.

v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]

Note 4 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and19 Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars and the Company has adopted a December 31 year end.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of June 30, 2023 and December 31, 2022, the Company had no cash equivalents.

 

The Company maintains one account at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of June 30, 2023 and December 31, 2022, the allowance for doubtful accounts was $0.

 

Inventory

 

The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of June 30, 2023 and December 31, 2022 the Company had $15,830 and $12,278 of finished goods on hand, respectively.

 

Income Taxes

 

The provision for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.

 

Revenue Recognition

 

The Company’s revenue is recognized in accordance with Accounting Standards Codification 606. The Company, through its online websites, operates in the Immune health supplement market. In addition to the website the Company has a Seller Central listing with Amazon and sells three products through the Amazon online platform. The Company offers products – Be-OnGuard Nasal Spray used against nasal bacteria, viruses and allergens; Be-OnGuard Mouth Spray used against oral bacteria, viruses and allergens; and Be-OnGuard EZ Safer Air used against airborne bacteria, viruses and allergens; Be On-Guard Brain Fog Support; and ADHD 365 maximum strength brain support. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers will remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. As of June 30, 2023 and December 31, 2022 deferred revenue was $0. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue.

 

Advertising Costs

 

Advertising costs are expensed as incurred. During the six months ended June 30, 2023 and 2022, the Company incurred advertising costs of $ 47,675 and $0, respectively.

 

Leases

 

The Company follows the provisions of ASC 842, and records right-of-use ("ROU") assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company's leases is not readily determinable, the Company's applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments.  The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.

 

The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.

 

As of June 30, 2023, the Company had a month-to-month rental agreement for their office and inventory space and paid rent expense of $3,584 for the six months ended June 30, 2023.

 

Net Income (Loss) per Common Share

 

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. There were no potentially dilutive common shares outstanding as of June 30, 2023 or 2022.

 

Recent Accounting Pronouncements

 

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements.

v3.23.2
Related Party Transactions
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]

Note 5 - Related Party Transactions

 

In support of the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. Amounts represent advances or amounts paid in satisfaction of liabilities.

 

During the six months ended June 30, 2023 the Company purchased $19,950 worth of inventory from Ageless Holdings, LLC (“Ageless”), an entity owned and controlled by the Company’s members of management and board of directors, $12,857 was owing as of June 30, 2023. Additionally, the Company received $180,574 worth of advances from Ageless to pay for operating expenses and the Company paid back $109,612 of the advances.

 

As of June 30, 2023 and December 31, 2022, the Company owed related parties a total of $116,318 and $45,356, respectively.

 

During the six months ended June 30, 2022 the Company’s CEO advanced the Company $202 and the Company purchased $12,090 worth of inventory from Ageless. Additionally, the Company received $26,000 worth of advances from Ageless to pay for operating expenses. The Company paid back $19,002 of the advances. The Company also issued 126,920 common shares to related parties for consulting services (see Note 6).

v3.23.2
Equity
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Equity [Text Block]

Note 6 - Equity

 

Common Stock

 

The Company has 75,000,000, $0.0001 par value shares of voting common stock authorized.

 

During the three months ended March 31, 2023, the Company issued 34,371,100 shares of common stock to Best shareholders in exchange for all of the shares of Best common stock (see Note 2) resulting in an increase in common stock of $3,437 and a decrease in additional paid-in-capital of $4,528.

 

During the three months ended June 30, 2023, the Company issued 480,000 common shares for cash proceeds of $120,000.

 

During the three months ended March 31, 2022, the Company issued 2,284,556 shares to third parties for consulting services valued at $4,050 and issued 126,920 shares to related parties for consulting services valued at $225.

 

During the three months ended June 30, 2022 there were no issuances of common stock.

 

As of June 30, 2023 and December 31, 2022, the Company had 40,312,600 and 5,461,500 shares of common stock issued and outstanding, respectfully.

 

Preferred Stock

 

On October 19, 2021, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing up to 5,000,000 shares of Preferred Stock, par value $0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted by the Board of Directors. On November 1, 2021, the Company filed a Certificate of Designation designating 1,000,000 shares of Preferred Stock as Series A Convertible Preferred Stock (the “Series A”). Each share of the Series A is convertible into three shares of the Company’s common stock at the holder's election, subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice.

 

During the six months ended June 30, 2023 and 2022 there were no issuances of preferred stock. As of June 30, 2023 and December 31, 2022, the Company had 140,000 shares of Series A Convertible Preferred Stock outstanding.

v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events [Text Block]

Note 7 - Subsequent Events

 

The Company has evaluated all events that occur after the balance sheet date through August 11, 2023, the date when the financial statements were available to be issued, to determine if they must be reported. Management of the Company determined that there are no material subsequent events to be disclosed other than those described below.

 

Subsequent to June 30, 2023, the Company received advances of $900 from related parties and made repayments of $26,600. On July 20, the Company issued 80,000 common shares for $20,000.

v3.23.2
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and19 Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars and the Company has adopted a December 31 year end.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of June 30, 2023 and December 31, 2022, the Company had no cash equivalents.

The Company maintains one account at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000.

Accounts Receivable [Policy Text Block]

Accounts Receivable and Allowance for Doubtful Accounts

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of June 30, 2023 and December 31, 2022, the allowance for doubtful accounts was $0.

Inventory, Policy [Policy Text Block]

Inventory

The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of June 30, 2023 and December 31, 2022 the Company had $15,830 and $12,278 of finished goods on hand, respectively.

Income Tax, Policy [Policy Text Block]

Income Taxes

The provision for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.

 

Revenue [Policy Text Block]

Revenue Recognition

The Company’s revenue is recognized in accordance with Accounting Standards Codification 606. The Company, through its online websites, operates in the Immune health supplement market. In addition to the website the Company has a Seller Central listing with Amazon and sells three products through the Amazon online platform. The Company offers products – Be-OnGuard Nasal Spray used against nasal bacteria, viruses and allergens; Be-OnGuard Mouth Spray used against oral bacteria, viruses and allergens; and Be-OnGuard EZ Safer Air used against airborne bacteria, viruses and allergens; Be On-Guard Brain Fog Support; and ADHD 365 maximum strength brain support. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers will remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. As of June 30, 2023 and December 31, 2022 deferred revenue was $0. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue.

Advertising Cost [Policy Text Block]

Advertising Costs

Advertising costs are expensed as incurred. During the six months ended June 30, 2023 and 2022, the Company incurred advertising costs of $ 47,675 and $0, respectively.

Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) per Common Share

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. There were no potentially dilutive common shares outstanding as of June 30, 2023 or 2022.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements.

v3.23.2
Reorganization & Recapitalization (Tables)
6 Months Ended
Jun. 30, 2023
Business Combinations [Abstract]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The following table summarizes the assets acquired and the liabilities assumed at the acquisition date of March 10, 2023:

Cash

  $ 8,793  

Accounts Payable

    (8,870

)

Credit Card Liability

    (1,014

)

Net Assets (Liabilities) Assumed

  $ (1,091

)

v3.23.2
Reorganization & Recapitalization (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 10, 2023
Feb. 13, 2023
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Reorganization & Recapitalization (Details) [Line Items]              
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual       $ 0      
Business Acquisition, Pro Forma Revenue       32,337      
Gross Profit     $ 59,966   $ 7,067 $ 87,557 $ 7,281
Operating Expenses     $ 145,228   $ 8,945 243,535 $ 13,370
Business Acquisition, Pro Forma Net Income (Loss)           89,826  
Best 365 Labs Inc. [Member]              
Reorganization & Recapitalization (Details) [Line Items]              
Equity Method Investment, Ownership Percentage 85.39% 100.00%          
Pro Forma [Member]              
Reorganization & Recapitalization (Details) [Line Items]              
Gross Profit           27,591  
Operating Expenses           $ 117,417  
Best 365 Labs Inc. [Member]              
Reorganization & Recapitalization (Details) [Line Items]              
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares) 34,371,100 9,588,000          
Nowtransit [Member]              
Reorganization & Recapitalization (Details) [Line Items]              
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized       $ 5,295      
v3.23.2
Reorganization & Recapitalization (Details) - Schedule of Business Acquisitions, by Acquisition
Mar. 10, 2023
USD ($)
Schedule Of Business Acquisitions By Acquisition Abstract  
Cash $ 8,793
Accounts Payable (8,870)
Credit Card Liability (1,014)
Net Assets (Liabilities) Assumed $ (1,091)
v3.23.2
Summary of Significant Accounting Policies (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Accounting Policies [Abstract]      
Cash, FDIC Insured Amount $ 250,000    
Accounts Receivable, Allowance for Credit Loss 0   $ 0
Inventory, Finished Goods, Gross 15,830   12,278
Deferred Revenue 0   $ 0
Advertising Expense 47,675 $ 0  
Operating Lease, Expense $ 3,584    
v3.23.2
Related Party Transactions (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Related Party Transactions (Details) [Line Items]        
Proceeds from Related Party Debt   $ 180,574 $ 38,292  
Repayments of Related Party Debt   109,612 19,002  
Stock Issued During Period, Shares, Issued for Services (in Shares) 2,284,556      
Ageless Holdings, LLC [Member]        
Related Party Transactions (Details) [Line Items]        
Other Inventory, Purchased Goods, Gross     12,090  
Proceeds from Related Party Debt   180,574 26,000  
Repayments of Related Party Debt   109,612 19,002  
Chief Executive Officer [Member]        
Related Party Transactions (Details) [Line Items]        
Proceeds from Related Party Debt     $ 202  
Affiliated Entity [Member] | Ageless Holdings, LLC [Member]        
Related Party Transactions (Details) [Line Items]        
Other Inventory, Purchased Goods, Gross   19,950    
Other Inventory, in Transit, Gross   12,857    
Related Party [Member]        
Related Party Transactions (Details) [Line Items]        
Other Liabilities   $ 116,318   $ 45,356
Stock Issued During Period, Shares, Issued for Services (in Shares) 126,920      
v3.23.2
Equity (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2023
Dec. 31, 2022
Equity (Details) [Line Items]          
Common Stock, Shares Authorized 75,000,000     75,000,000 75,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.0001     $ 0.0001 $ 0.0001
Stock Issued During Period, Shares, Other   34,371,100      
Stock Issued During Period, Value, Other (in Dollars)   $ (1,091)      
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs (in Dollars)   4,528      
Stock Issued During Period, Shares, New Issues 480,000        
Stock Issued During Period, Value, New Issues (in Dollars) $ 120,000        
Stock Issued During Period, Shares, Issued for Services     2,284,556    
Stock Issued During Period, Value, Issued for Services (in Dollars)     $ 4,050    
Common Stock, Shares, Issued 40,312,600     40,312,600 5,461,500
Common Stock, Shares, Outstanding 40,312,600     40,312,600 5,461,500
Preferred Stock, Shares Authorized 5,000,000     5,000,000  
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) $ 0.0001     $ 0.0001 $ 0.0001
Preferred Stock, Conversion Basis       Each share of the Series A is convertible into three shares of the Company’s common stock at the holder's election, subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice  
Preferred Stock, Shares Outstanding 140,000     140,000 140,000
Series A Preferred Stock [Member]          
Equity (Details) [Line Items]          
Preferred Stock, Shares Authorized 1,000,000     1,000,000  
Preferred Stock, Shares Outstanding 140,000     140,000 140,000
Best 365 Labs Inc. [Member]          
Equity (Details) [Line Items]          
Stock Issued During Period, Value, Other (in Dollars)   $ 3,437      
Related Party [Member]          
Equity (Details) [Line Items]          
Stock Issued During Period, Shares, Issued for Services     126,920    
Stock Issued During Period, Value, Issued for Services (in Dollars)     $ 225    
v3.23.2
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
1 Months Ended
Jul. 20, 2023
Jul. 20, 2023
Subsequent Events (Details) [Line Items]    
Proceeds from Related Party Debt   $ 900
Repayments of Related Party Debt   $ 26,600
Debt Conversion, Converted Instrument, Shares Issued (in Shares) 80,000  
Debt Conversion, Converted Instrument, Amount $ 20,000  

Nowtransit (PK) (USOTC:NOTR)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Nowtransit (PK) Charts.
Nowtransit (PK) (USOTC:NOTR)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Nowtransit (PK) Charts.